AMTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amentum Holdings Inc (AMTM) does not currently present a strong buy opportunity for a beginner investor with a long-term focus. While the company has secured a significant AI-powered supply chain contract and shows potential for modest growth, the technical indicators, analyst sentiment, and hedge fund activity suggest caution. The lack of strong proprietary trading signals further supports a hold recommendation.
The technical indicators for AMTM are bearish. The MACD histogram is negative and expanding downward, RSI is neutral at 33.192, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 21.294), with resistance levels at R1: 23.176 and R2: 23.757. This suggests limited upward momentum in the short term.
Amentum recently secured a $77 million contract from the General Services Administration to provide AI-powered supply chain solutions for the Pentagon over 60 months. This demonstrates the company's ability to secure high-value government contracts, which could contribute to long-term revenue growth.
Analysts have expressed concerns about Amentum's organic growth and margins falling behind peers. Hedge funds are aggressively selling, with a 3056.33% increase in selling activity over the last quarter. Additionally, the stock's technical indicators and bearish moving averages suggest limited near-term upside.
No financial data or valuation metrics are available for the latest quarter, making it difficult to assess the company's recent financial performance. However, analysts have noted flat year-over-year revenues in Q2, with headwinds from divestitures and JV transitions.
Analyst sentiment is mixed to negative. BNP Paribas initiated coverage with an Underperform rating and a $22 price target, citing concerns about growth and margins. JPMorgan and RBC Capital lowered their price targets to $31 and $28, respectively, while maintaining neutral or sector perform ratings. Truist remains more optimistic with a Buy rating but reduced its price target to $35.
